We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NB11 market cap is 164.35M. The company's latest EPS is USD -0.3625 and P/E is -2.04.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.86M | 4.9M | 892k | 107k | 7.38M |
| Operating Income | -15.79M | -30.17M | -72.75M | -114.59M | -83.35M |
| Net Income | -18.65M | -32.22M | -70.47M | -107.76M | -82.47M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 37.03M | 152.58M | 221.17M | 153.85M | 91.83M |
| Total Liabilities | 24.08M | 29.18M | 33.64M | 43.25M | 34.03M |
| Total Equity | 12.95M | 123.4M | 187.53M | 110.6M | 57.81M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -13.09M | -23.75M | -59.83M | -94.78M | -70.45M |
| Investing | -850k | -1.22M | -49.1M | -20.42M | 43.95M |
| Financing | 15.96M | 138.31M | 125.8M | 17.46M | 15.24M |
| Market Cap | 164.35M |
| Price to Earnings Ratio | -2.04 |
| Price to Sales Ratio | 22.84 |
| Price to Cash Ratio | 4.84 |
| Price to Book Ratio | 2.91 |
| Dividend Yield | - |
| Shares Outstanding | 227.48M |
| Average Volume (1 week) | 10.61k |
| Average Volume (1 Month) | 16.09k |
| 52 Week Change | 4.62% |
| 52 Week High | 1.45 |
| 52 Week Low | 0.4968 |
| Spread (Intraday) | 0.04 (5.39%) |
| Company Name | Vaxart Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://vaxart.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
